Praluent Shortage Update: What Patients Need to Know in 2026

If you've been prescribed Praluent (alirocumab) and are struggling to get it filled, you may be wondering whether there's an official shortage. Here's the updated status for 2026 and a clear breakdown of what's actually happening with Praluent access.

Official Shortage Status: Not Listed as of 2026

As of 2026, Praluent (alirocumab) is NOT on the FDA Drug Shortages database or the ASHP drug shortage list. Regeneron Pharmaceuticals and Sanofi, who manufacture and distribute Praluent, have not issued any public statements about manufacturing disruptions or supply constraints.

The product exists. It is being manufactured. The challenge is getting it from the manufacturer to patients — a problem driven by systemic access barriers, not a supply chain failure.

Why Patients Still Face Access Challenges

Despite no manufacturing shortage, a meaningful percentage of patients prescribed Praluent experience delays or inability to fill their prescriptions. The key reasons:

1. Prior Authorization Denials and Delays

Prior authorization (PA) is required by virtually all commercial and Medicare plans for Praluent. The PA process requires documentation of cardiovascular disease or familial hypercholesterolemia, maximally tolerated statin therapy, and LDL-C levels above a threshold. First-round PA denials are common, and the appeals process adds weeks of delay.

2. Specialty Pharmacy Logistics

Praluent is distributed primarily through specialty pharmacies, not retail chains. Most retail locations don't stock it due to refrigeration requirements, low per-location prescription volume, and high per-unit cost ($533–$777 per month). Patients must navigate their insurance plan's specialty pharmacy network, which isn't always obvious or convenient.

39,483+ patients found their medications in stock

39K+

Find Praluent In Stock Today →

3. Formulary Restrictions

Some insurance formularies prefer Repatha (evolocumab) over Praluent, or require step therapy through ezetimibe first. Only about 50% of commercial insurance members have coverage for Praluent, while Medicaid covers nearly all enrollees. Medicare Part D coverage varies by plan.

4. Cost Barriers

Without insurance, Praluent costs approximately $533–$777 per month for a two-pen supply — around $5,850 per year at list price. Even with insurance and the MyPRALUENT Copay Card (which can reduce commercially insured patients' costs to $35–$50/month), some patients face cost obstacles, particularly Medicare beneficiaries who cannot use manufacturer copay cards.

Skip the calls, skip the stress.

Find Praluent In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

What Has Changed in 2026?

Some positive developments in 2026 have improved the landscape for PCSK9 inhibitor access:

Medicare Part D out-of-pocket cap. The Inflation Reduction Act's $2,100 annual out-of-pocket cap on Part D drugs means Medicare patients who reach the cap pay $0 for the rest of the year — a significant improvement for patients on expensive biologics like Praluent.

Streamlined PA criteria for high-risk patients. Some payers have simplified prior authorization requirements for patients with documented ASCVD and very high LDL-C, reducing the administrative burden for clear-cut cases.

No biosimilar competition yet: While biosimilar PCSK9 inhibitors are in development, none had received FDA approval as of 2026 — meaning patients continue to have only brand-name Praluent available.

What Patients Can Do Right Now

If you're having trouble getting Praluent filled in 2026, here are concrete steps:

Confirm your PA status. Call your insurance company to confirm whether a prior authorization has been submitted, approved, or denied. If denied, ask about the appeals process.

Ask your doctor's office about PA support. Many cardiology practices have staff who specialize in prior authorization submissions and appeals.

Apply for the MyPRALUENT Copay Card or PAP. Call 1-844-772-5836 or visit praluent.com. The patient assistance program may provide Praluent at no charge for eligible uninsured patients.

Use medfinder. medfinder.com calls pharmacies near you to find which ones have Praluent in stock, saving you hours of calls.

The Bottom Line

Praluent is not in an FDA-recognized shortage, but access remains genuinely difficult for many patients due to insurance logistics, specialty pharmacy distribution, and cost. The barriers are real — but so are the workarounds. If you've tried everything and still can't access Praluent, talk to your doctor about clinically appropriate alternatives like Repatha or Leqvio.